Title: Heat shock protein 90 inhibitors induce functional inhibition of human natural killer cells in a dose-dependent manner.
Journal: Immunopharmacology and immunotoxicology 20160101
Title: Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases.
Journal: Bioorganic & medicinal chemistry letters 20140101
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: EC144 is a potent inhibitor of the heat shock protein 90.
Journal: Journal of medicinal chemistry 20120913
Title: In vitro metabolism of BIIB021, an inhibitor of heat shock protein 90, in liver microsomes and hepatocytes of rats, dogs, and humans and recombinant human cytochrome P450 isoforms.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20120401
Title: ATPases as drug targets: insights from heat shock proteins 70 and 90.
Journal: Journal of medicinal chemistry 20101028
Title: BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.
Journal: International journal of cancer 20100301
Title: BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance.
Journal: International journal of cancer 20100301
Title: An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors.
Journal: Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 20100201
Title: Heat shock protein 90: inhibitors in clinical trials.
Journal: Journal of medicinal chemistry 20100114
Title: Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090815
Title: BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.
Journal: Molecular cancer therapeutics 20090401
Title: Discovery and development of heat shock protein 90 inhibitors.
Journal: Bioorganic & medicinal chemistry 20090315
Title: Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
Journal: Journal of medicinal chemistry 20070614
Title: Lundgren, Karen., et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Molecular Cancer Therapeutics (2009), 8(4), 921-929.
Title: B?ll B, et al. Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity. Clin Cancer Res. 2009 Aug 15;15(16):5108-16.
Title: Yin X, et al. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int J Cancer. 2010 Mar 1;126(5):1216-25
Title: Zhang H, et al. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance. Int J Cancer. 2010 Mar 1;126(5):1226-34
